Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.58 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.58 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.57 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.57 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2784571 | 1.00 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL19534565 | 0.90 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL11880551 | 0.86 | P2RY2 (0.50) | P2RY6P2RY2P2RY14 | |
| SCHEMBL5583994 | 0.86 | P2RY2 (0.50) | P2RY6P2RY2P2RY14 | |
| SCHEMBL14583149 | 0.85 | P2RY14 (0.73) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL12015068 | 0.85 | P2RY14 (0.73) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL14414535 | 0.85 | P2RY14 (0.73) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL14027758 | 0.85 | P2RY6 (0.58) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL14088634 | 0.85 | P2RY14 (0.73) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL12361501 | 0.85 | P2RY14 (0.73) | P2RY6P2RY2P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100291118-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | INNATE PHARMA (FR) | 2010-11-18 | — | — | US | disclosed |
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | INNATE PHARMA, S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-20100222306-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | INNATE PHARMA, S.A. (FR) | 2010-09-02 | — | — | US | disclosed |
| US-7767842-B2 | Class of γδ T cells activators and use thereof | INNATE PHARMA SA (FR) | 2010-08-03 | — | — | US | disclosed |
| US-7683045-B2 | Class of γδ T cells activators and use thereof | INNATE PHARMA S.A. (FR) | 2010-03-23 | — | — | US | disclosed |
| EP-1569656-B1 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | INNATE PHARMA (FR) | 2010-03-03 | — | — | EP | disclosed |
| EP-1761278-B1 | ADJUVANT COMPOSITION AND METHODS FOR ITS USE | INNATE PHARMA (FR) | 2008-12-31 | — | — | EP | disclosed |
| US-20080207568-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | INNATE PHARMA S.A. (FR) | 2008-08-28 | — | — | US | disclosed |
| CN-101146575-A | New class of gamma delta T cells activators and use thereof | INNATE PHARMA SA (FR) | 2008-03-19 | — | — | CN | disclosed |
| EP-1863572-A2 | NEW CLASS OF T CELLS ACTIVATORS AND USE THEREOF | Innate Pharma (FR) | 2007-12-12 | — | — | EP | disclosed |
| CN-1890252-A | Novel class of gamma delta T cell activators and uses thereof | INNATE PHARMA (FR) | 2007-01-03 | — | — | CN | disclosed |
| EP-1720567-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA | Innate Pharma (FR) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006103568-A2 | NEW CLASS OF Ϝδ T CELLS ACTIVATORS AND USE THEREOF | INNATE PHARMA (FR) | 2006-10-05 | — | — | WO | disclosed |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | INNATE PHARMA, S.A.S. (FR) | 2006-08-31 | — | — | US | disclosed |
| EP-1689758-A2 | NEW CLASS OF GAMMA DELTA T CELLS ACTIVATORS AND USE THEREOF | Innate Pharma (FR) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005102385-A1 | ADJUVANT COMPOSITION AND METHODS FOR ITS USE | INNATE PHARMA (FR) | 2005-11-03 | — | — | WO | disclosed |
| EP-1569656-A2 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | Innate Pharma (FR) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005077411-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF CARCINOMA | INNATE PHARMA (FR) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005054258-A2 | NEW CLASS OF GAMMA DELTA T CELLS ACTIVATORS AND USE THEREOF | INNATE PHARMA (FR) | 2005-06-16 | — | — | WO | disclosed |
| WO-2004050096-A2 | PHOSPHOANTIGENS FOR REGULATING AN IMMUNE RESPONSE | INNATE PHARMA (FR) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254940-A1 | Compositions and Methods for Regulating an Immune Response in a Subject | IFNG, IL2, ICOS | SLC28A1 4031/4885SLC28A2 4129/4885SLC29A1 3345/4885 |
| US-20080207568-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | NFATC1, CD4, CD74 | SLC28A1 4164/4885SLC28A2 4076/4885SLC29A1 3500/4885 |
| US-20100291118-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | CD4, IFNG, NFATC1 | SLC28A1 4007/4885SLC28A2 4258/4885SLC29A1 3277/4885 |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | IFNG, IL2, ICOS | SLC28A1 4092/4885SLC28A2 4187/4885SLC29A1 3344/4885 |
| US-20100222306-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | NFATC1, CD4, CD74 | SLC28A1 4164/4885SLC28A2 4076/4885SLC29A1 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.